RGEN Kronos AI forecast
A 30-trading-day price forecast for Repligen Corporation (RGEN) from Kronos AI, an open-source foundation model trained on candlestick charts.
Kronos AI's median forecast puts Repligen Corporation at $153.12 on 2026-12-08, −12.9% from the last close of $175.80 on 2026-10-27. Eight out of ten sampled paths end between $149.48 and $175.17, and 1 of the 8 paths finish above today's price.
Forecast path
median, with the 10–90% band of the sampled pathsOpen the interactive forecast → Full analysis of RGEN
The forecast, week by week
| Date | Median | Low (10%) | High (90%) |
|---|---|---|---|
| 2026-11-03 | $179.26 | $176.05 | $186.64 |
| 2026-11-10 | $182.34 | $169.90 | $195.51 |
| 2026-11-17 | $170.98 | $168.15 | $192.69 |
| 2026-11-24 | $169.71 | $161.02 | $178.96 |
| 2026-12-01 | $165.70 | $163.06 | $179.20 |
| 2026-12-08 | $153.12 | $149.48 | $175.17 |
What is Kronos AI?
Kronos is an open-source foundation model for financial candlesticks, pre-trained on K-line data from more than 45 exchanges. Gnzub runs it on each stock's last 120 daily bars and samples several possible futures, so the forecast is a range of outcomes rather than one confident line. It is a statistical model, not an analyst: it reads price patterns only and knows nothing about news, earnings or the business.
Questions
- What is the Kronos AI forecast for RGEN?
- Kronos AI's median forecast for RGEN is $153.12 in 30 trading days, −12.9% from the last close, with a 10–90% range of $149.48 to $175.17.
- Is the RGEN Kronos forecast a buy or sell signal?
- No. It is the output of a statistical model that reads price history only. It is not investment advice, and the range shows how uncertain the model is.
- How often is the forecast updated?
- The forecasts are regenerated regularly; this one starts from the close of 2026-10-27.
Kronos forecasts for similar companies
- AMGN — Amgen Inc.
- GILD — Gilead Sciences Inc.
- MRNA — Moderna Inc.
- ARGX — argenx SE American Depositary Shares
- RVMD — Revolution Medicines Inc.
- BIIB — Biogen Inc.